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Summary We retrospectively analysed neuromuscular toxicity associated with paclitaxel 210 mg m-2 given by 3-h infusion in 247 patients.
The severity correlated significantly with total cumulative dose, but could not be predicted by the pretreatment clinical variables or by
pharmacokinetic parameters. The toxicity tended to occur in early treatment cycles.
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Peripheral neuropathy and myalgia/arthralgia are among the
significant toxicities of paclitaxel. It has been reported that
neuropathy associated with paclitaxel by a 24-h injection is depen-
dent upon total cumulative dosage, and no known risk factors have
been identified (Wiemik et al, 1987; Chaudhry et al, 1994). Little
information is available on the pharmacokinetics and this toxicity.
There are also few reports of neuromuscular toxicity of the drug
given by shorter infusion, the currently preferred method of
administration (Gianni, 1995).
The aim of this retrospective analysis was to evaluate the risk
factors for neuromuscular toxicity associated with paclitaxel by a
3-h infusion. Pharmacodynamics were also analysed in patients in
whom pharmacokinetic data were available.
PATIENTS AND METHODS
A retrospective analysis was performed on four phase II trials of
paclitaxel at a dose of 210 mg m-2 given as a 3-h infusion. Two
trials included patients with non-small-cell lung cancer, one trial
patients with breast cancer and the other trial patients with ovarian
cancer. A summary ofthe patient characteristics is given in Table 1.
Paclitaxel was supplied by Bristol-Myers Squibb (Tokyo,
Japan) as a solution containing 30 mg of the drug in 5 ml of 50%
polyoxyethylated castor oil (Cremophor EL) and 50% dehydrated
alcohol. Each patient received 210 mg m-2 paclitaxel diluted in
500 ml of 5% glucose in a 3-h i.v. infusion, every 3 weeks.
Adverse reactions to paclitaxel were graded according to the
toxicity criteria of the Japan Society for Cancer Therapy (Japan
Society for Cancer Therapy, 1993).
Pharmacokinetic analysis was performed during the first course
of the treatment in 50 patients. Heparinized blood samples for the
measurement of plasma paclitaxel concentration were collected
before the infusion and at 5, 15 and 30 min, and 1, 2, 3, 4, 6, 12, 24
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and 48 h after the end of the infusion. The following pharmaco-
kinetic parameters were calculated and correlated with toxicity:
peak plasma concentration (Cmax), area under the plasma concentra-
tion vs time curve (AUC) and the duration of the paclitaxel
concentration above 0.1 tM.
Spearman's correlation coefficient was used to determine the
correlation between two variables. The difference in the grade of
toxicity between the two groups was evaluated using the
Mann-Whitney U-test.
RESULTS
The median number of paclitaxel chemotherapy cycles was three
(range 1-15), and the median cumulative dose of the drug was
630 mg m-2 (range 35-3150mg m-2).
Peripheral neuropathy was grade 0 in 51 (21%), grade I in 120
(49%), grade 2 in 64 (26%) and grade 3 in 12 (5%) patients; no
patient suffered grade 4 neuropathy. The neuropathy was predom-
inantly sensory, and only five patients (four with grade 2 and one
with grade 3) experienced motor neuropathy. The severity of
myalgia/arthralgia was grade 0 in 88 (36%), grade 1 in 74 (30%),
grade 2 in 79 (32%) and grade 3 in six (2%) patients.
In accordance with earlier reports (Wiernik et al, 1987; Postma
et al, 1995), neuromuscular toxicity showed a significant correla-
tion with the total cumulative dose of paclitaxel. Spearman's
correlation coefficient was 0.343 (P < 0.0001) for neuropathy and
total dose, and 0.218 (P = 0.0006) for myalgia/arthralgia and total
dose. Age, sex, height (which should reflect length of peripheral
nerve), prior chemotherapy, renal or hepatic function, and the
metastatic sites did not show a significant correlation with
neuromuscular toxicity. Although a higher serum total protein
concentration showed a significant (P = 0.020) correlation with
neuropathy, the degree of correlation was weak (r = 0.15) and
inconsistent among subsets of the population. There was no
correlation between any of the pharmacokinetic parameters and
occurrence of neuromuscular toxicity.
Although the neuromuscular toxicity seemed to be dependent
on the total dose, it did occur during the early treatment cycles.
Of the 76 patients who experienced grade 2 or 3 peripheral
neuropathy, 68 (89%) had at least grade 1 and 31 (41%) had at
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Table 1 Patient characteristics (n = 247)
Characteristics No. %
Primary tumour
Lung (non small cell) 120 48.6
Breast 62 25.1
Ovary 65 26.3
Sex
Male 94 38.1
Female 153 61.9
Median age (years) (range) 60 (21-74)
Performance status
0 92 37.2
1 127 51.4
2 28 11.3
Metastatic site
Brain 13 5.3
Bone 55 22.3
Liver 48 19.4
Pleural effusion 38 15.4
Ascites 2 0.8
Prior chemotherapy
None 120 48.6
Non-cisplatin 65 26.3
Cisplatin containing 62 25.1
Table 2 Outcome of neuromuscular toxicity
Completely Partly Median
reversible reversible Persistenta follow-up
time (days)
No. % No. % No. %
Peripheral neuropathy
Grade 1 61 51 9 8 50 42 198
Grade 2 27 42 16 25 21 33 237
Grade 3 5 42 1 8 6 50 142
Myalgia/arthralgia
Grade 1 67 91 0 0 7 9 217
Grade 2 73 92 4 5 2 3 221
Grade 3 4 67 0 0 2 33 245
a'Persistent' means little or no improvement in the symptom at the end of the
follow-up periods (from completion of therapy and the last observation).
least grade 2 neuropathy after the first course. With regard to
myalgia/arthralgia, ofthe 85 patients whoexperienced grade 2 or 3
toxicity, 80 (94%) had at least grade 1 and 68 (80%) had at least
grade 2 myalgia/arthralgia after the first course. Among those who
experienced grade 0 and grade 1 neuropathy after the first course,
62 and 102 patients, respectively, received three or more courses
ofpaclitaxel. Grade 2 or 3 neuropathy developed in eight (13%) of
the former group and 33 (32%) ofthe latter group (P = 0.009).
Table 2 summarizes the outcome of the neuromuscular toxicity
at the end of the follow-up period (median follow-up period from
the end of chemotherapy for all cases was 181 days). Peripheral
neuropathy tended to be more persistent. There was no apparent
correlation between severity and reversibility.
DISCUSSION
Among the major toxicities of paclitaxel, neutropenia has been
shown to be schedule dependent (Tamura et al, 1994; Gianni et al,
1995; Ohtsu et al, 1995; Tamura et al, 1995). As for neuro-
muscular toxicity, although neuropathy and myalgia/arthralgia
appeared to be more severe in a phase I trial in which a shorter
infusion was used (Schiller et al, 1994), the results of a random-
ized trial with moderate dosages of paclitaxel have not supported
its schedule dependency (Eisenhauer et al, 1994).
In the present study, we have described the clinical course of
neuromuscular toxicity associated with 3-h infusion of paclitaxel.
It could not be predicted by pretreatment variables or pharmaco-
kinetic parameters. While myalgia/arthralgia was usually
completely reversible, peripheral neuropathy was often persistent.
Both peripheral neuropathy and myalgia/arthralgia showed a
significant correlation with the total cumulative dose; however,
they appeared during the early treatment courses in the majority of
patients with significant toxicity. This seems to contradict the
notion that paclitaxel-induced neuromuscular toxicity is dependent
on the cumulative dose, but is consistent with an earlier report
by Postma et al (1995). They reported that paclitaxel-induced
neuropathy was observed after one course of a higher dose of
paclitaxel (250-300 mg m-2) given by a 3-h infusion. This was not
the case with the lower dose (135-175 mg m-2) of paclitaxel.
However, it is important to note that a lower dose ofpaclitaxel per
course does lead to neuropathy when the cumulative dose is higher
(Eisenhauer et al, 1994; Postma et al, 1995; Tamura et al, 1995).
Thus, there does not seem to be a 'threshold' dose per course
below which neuropathy does not occur. It seems, therefore, that
the pattern by which paclitaxel induces neuromuscular toxicity
appears to be different between the higher and the lower dosages.
There are very few basic data that shed light on the schedule or
dose per course dependency ofthis toxicity.
In conclusion, although neuromuscular toxicity associated with
paclitaxel at a dose of 210 mg m-2 given by 3-h infusion is depen-
dent on the cumulative dose, it is not predictable from baseline
patient characteristics. It can, however, usually be recognized
early in the treatment cycles. Careful monitoring for neuropathy is
necessary as the toxicity tends to persist long after completion of
therapy.
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